Dolutegravir + lamivudine + tenofovir

General description

INN	Dolutegravir + lamivudine + tenofovir
ATC codes	J05AR27
Medicine type	Chemical agent
EML status history	First added in 2019 (TRS 1021) for Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Wikipedia	Dolutegravir + lamivudine + tenofovir
DrugBank	Dolutegravir, Lamivudine, Tenofovir (Tenofovir disoproxil)

Recommendations

Section Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified